Clinical Programs
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Onvansertib in combination with nanoliposomal irinotecan and 5-FU for second-line treatment of patients to improve response rates and progression-free survival over SoC alone.
Efficacy End Points
- Primary: Objective response rate in patients who receive ≥28-days of treatment
- Secondary: Duration of response and median overall survival
- Exploratory: Identification of biomarkers related to sensitivity and resistance to treatment using patient-derived organoids, blood samples, and archival tissue biopsies
Proof of Concept Criteria
- 20% objective response rate
- ≥6 months median progression-free survival